Oncostatin-M: A new bone active cytokine that activates osteoblasts and inhibits bone resorption

被引:74
作者
Jay, PR
Centrella, M
Lorenzo, J
Bruce, AG
Horowitz, MC
机构
[1] YALE UNIV, SCH MED, DEPT ORTHOPAED & REHABIL, NEW HAVEN, CT 06520 USA
[2] YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06520 USA
[3] VET ADM MED CTR, NEWINGTON, CT 06111 USA
[4] UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT USA
[5] BRISTOL MYERS SQUIBB, SEATTLE, WA 98121 USA
关键词
D O I
10.1210/en.137.4.1151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoblasts and their precursors respond to specific cytokines, growth factors, and hormones. One facet of this response includes the secretion of additional cytokines, some of which are part of the circuitry involved in the regulation of osteoblast and osteoclast function. Therefore, understanding which cytokines are able to activate osteoclastic cells and the consequences of that activation are central to understanding normal and pathologic bone remodeling. Oncostatin M (OSM) is a glycoprotein belonging to a new subfamily of cytokines related by sequence and structural homology and the use of the signal transducing receptor component gp130. Osteoblastic cells secrete and respond to leukemia-inhibiting factor (LIF) both in vitro and in vivo, suggesting that LIF is an autocrine regulatory factor. OSM is closely related to LIF, and therefore we hypothesized that OSM should regulate the function of cells in the osteoblastic lineage. Primary neonatal murine or fetal rat calvarial osteoblastic cultures were treated with OSM or LIF and a series of biochemical and biological parameters were determined. In these cultures, OSM induced proliferation, collagen synthesis, and interleukin-6 secretion, whereas it inhibited alkaline phosphatase activity. Bone resorption was also inhibited by OSM. These data represent the first report of OSM's effects on bone cell function and indicate that, like some other members of the LIF/interleukin-6 subfamily, OSM has potent bone regulatory activity.
引用
收藏
页码:1151 / 1158
页数:8
相关论文
共 66 条
[1]  
ALHUMIDAN A, 1991, J BONE MINER RES, V6, P3
[2]   OSTEOBLASTS DISPLAY RECEPTORS FOR AND RESPONSES TO LEUKEMIA-INHIBITORY FACTOR [J].
ALLAN, EH ;
HILTON, DJ ;
BROWN, MA ;
EVELY, RS ;
YUMITA, S ;
METCALF, D ;
GOUGH, NM ;
NG, KW ;
NICOLA, NA ;
MARTIN, TJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1990, 145 (01) :110-119
[3]  
BARTON B E, 1990, Cytokine, V2, P217, DOI 10.1016/1043-4666(90)90019-P
[4]   ONCOSTATIN-M STIMULATES PROLIFERATION IN B9 HYBRIDOMA CELLS - POTENTIAL ROLE OF ONCOSTATIN-M IN PLASMACYTOMA DEVELOPMENT [J].
BARTON, BE ;
JACKSON, JV ;
LEE, F ;
WAGNER, J .
CYTOKINE, 1994, 6 (02) :147-153
[5]   STIMULATION OF BONE-RESORPTION AND INHIBITION OF BONE-FORMATION INVITRO BY HUMAN-TUMOR NECROSIS FACTORS [J].
BERTOLINI, DR ;
NEDWIN, GE ;
BRINGMAN, TS ;
SMITH, DD ;
MUNDY, GR .
NATURE, 1986, 319 (6053) :516-518
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   REGULATION OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR EXPRESSION BY ONCOSTATIN-M [J].
BROWN, TJ ;
LIU, JW ;
BRASHEMSTEIN, C ;
SHOYAB, M .
BLOOD, 1993, 82 (01) :33-37
[8]  
BROWN TJ, 1991, J IMMUNOL, V147, P2175
[9]  
BROWN TJ, 1987, J IMMUNOL, V139, P2977
[10]  
BROWN TJ, 1990, MOL BIOL CARDIOVASC, V131, P195